119 related articles for article (PubMed ID: 10760815)
21. Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction.
Kitagawa N; Goto M; Kurozumi K; Maruo S; Fukayama M; Naoe T; Yasukawa M; Hino K; Suzuki T; Todo S; Takada K
EMBO J; 2000 Dec; 19(24):6742-50. PubMed ID: 11118209
[TBL] [Abstract][Full Text] [Related]
22. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus.
Ernberg I; Falk K; Minarovits J; Busson P; Tursz T; Masucci MG; Klein G
J Gen Virol; 1989 Nov; 70 ( Pt 11)():2989-3002. PubMed ID: 2479717
[TBL] [Abstract][Full Text] [Related]
23. Improvement of nonviral gene therapy by Epstein-Barr virus (EBV)-based plasmid vectors.
Mazda O
Curr Gene Ther; 2002 Sep; 2(3):379-92. PubMed ID: 12189722
[TBL] [Abstract][Full Text] [Related]
24. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.
Cherney BW; Bhatia KG; Sgadari C; Gutierrez MI; Mostowski H; Pike SE; Gupta G; Magrath IT; Tosato G
Cancer Res; 1997 Jun; 57(12):2508-15. PubMed ID: 9192833
[TBL] [Abstract][Full Text] [Related]
25. Induction of CD44 expression by the Epstein-Barr virus latent membrane protein LMP1 is associated with lymphoma dissemination.
Walter J; Schirrmacher V; Mosier D
Int J Cancer; 1995 May; 61(3):363-9. PubMed ID: 7537255
[TBL] [Abstract][Full Text] [Related]
26. Burkitt's lymphoma - a human tumor model system for immunological studies.
Gunvén P
Biochim Biophys Acta; 1975 Dec; 417(3-4):187-210. PubMed ID: 175835
[TBL] [Abstract][Full Text] [Related]
27. [Cytokine-regulating activity of anti-virus preparation CelAgripus in Burkitt's lymphoma stable B-cell lines.].
Narovlyansky AN; Mezentseva MV; Suetina IA; Russu LI; Ivanova AM; Poloskov VV; Izmest'eva AV; Ospelnikova TP; Sarymsakov AA; Ershov FI
Vopr Virusol; 2019; 64(4):165-172. PubMed ID: 32163682
[TBL] [Abstract][Full Text] [Related]
28. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.
Hong M; Murai Y; Kutsuna T; Takahashi H; Nomoto K; Cheng CM; Ishizawa S; Zhao QL; Ogawa R; Harmon BV; Tsuneyama K; Takano Y
J Cancer Res Clin Oncol; 2006 Jan; 132(1):1-8. PubMed ID: 16180023
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus genome studies in Burkitt's and non-Burkitt's lymphomas in Uganda.
Olweny CL; Atine I; Kaddu-Mukasa A; Owor R; Andersson-Anvret M; Klein G; Henle W; de-Thé G
J Natl Cancer Inst; 1977 May; 58(5):1191-6. PubMed ID: 192894
[TBL] [Abstract][Full Text] [Related]
30. Differences in human cell lines to support stable replication of Epstein-Barr virus-based vectors.
Vidal M; Wrighton C; Eccles S; Burke J; Grosveld F
Biochim Biophys Acta; 1990 Apr; 1048(2-3):171-7. PubMed ID: 2157493
[TBL] [Abstract][Full Text] [Related]
31. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
Gregory CD; Rowe M; Rickinson AB
J Gen Virol; 1990 Jul; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
[TBL] [Abstract][Full Text] [Related]
32. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1.
Hu LF; Chen F; Zheng X; Ernberg I; Cao SL; Christensson B; Klein G; Winberg G
Oncogene; 1993 Jun; 8(6):1575-83. PubMed ID: 8389032
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.
Vockerodt M; Tesch H; Kube D
Genes Immun; 2001 Dec; 2(8):433-41. PubMed ID: 11781710
[TBL] [Abstract][Full Text] [Related]
34. Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells.
Tosato G; Sgadari C; Taga K; Jones KD; Pike SE; Rosenberg A; Sechler JM; Magrath IT; Love LA; Bhatia K
Blood; 1994 Feb; 83(3):776-84. PubMed ID: 8298139
[TBL] [Abstract][Full Text] [Related]
35. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma.
Miyauchi K; Urano E; Yoshiyama H; Komano J
Cancer Sci; 2011 Jun; 102(6):1236-41. PubMed ID: 21392167
[TBL] [Abstract][Full Text] [Related]
36. CD40 cross-linking enhances the immunogenicity of Burkitt's-lymphoma cell lines.
Frisan T; Donati D; Cervenak L; Wilson J; Masucci MG; Bejarano MT
Int J Cancer; 1999 Dec; 83(6):772-9. PubMed ID: 10597194
[TBL] [Abstract][Full Text] [Related]
37. Influence of Epstein-Barr virus latent gene expression on the apoptosis-inducing effects of cortisone and 2-chlorodeoxyadenosine (2-CDA) in B-cell lines.
Röth A; Pfaff P; Lange W; Finke J
Cytokines Mol Ther; 1996 Mar; 2(1):21-8. PubMed ID: 9384686
[TBL] [Abstract][Full Text] [Related]
38. Replacement of the Epstein-Barr virus plasmid with the EBER plasmid in Burkitt's lymphoma cells.
Maruo S; Nanbo A; Takada K
J Virol; 2001 Oct; 75(20):9977-82. PubMed ID: 11559830
[TBL] [Abstract][Full Text] [Related]
39. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.
Guedez L; McMarlin AJ; Kingma DW; Bennett TA; Stetler-Stevenson M; Stetler-Stevenson WG
Am J Pathol; 2001 Apr; 158(4):1207-15. PubMed ID: 11290537
[TBL] [Abstract][Full Text] [Related]
40. Absence of IL-6 receptor expression in fresh childhood Burkitt's lymphoma cells and induction of IL-6 receptors by Epstein-Barr virus in vitro.
Tomeczkowski J; zur Stadt U; Reiter A; Welte K; Sykora KW
Br J Haematol; 1997 May; 97(2):400-8. PubMed ID: 9163607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
